针对风湿关节炎患者的远程定制远程控制:iARPlus (风湿病学的创新方法) 倡议
Fausto Salaffi1, Sonia Farah1, Eleonora Di Donato1
1Rheumatology Unit, Università Politecnica delle Marche, "Carlo Urbani" Hospital, Via Aldo Moro, 25, 60035 Jesi, Italy.
Journal of personalized medicine
|January 24, 2025
概括
类风湿关节炎影响疾病 (RAID) 评分有效监测类风湿关节炎 (RA) 活动在电话咨询期间. 雅努斯激酶抑制剂 (JAKis) 对 RA 患者的治疗结果比阿达利姆巴更好.
科学领域:
- 类风湿病学 类风湿病学
- 数字健康数字健康
- 患者报告的结果
背景情况:
- 风湿性关节炎 (RA) 管理受益于加强患者监测.
- 远程控制策略旨在改善慢性疾病管理中的患者结果.
研究的目的:
- 评估在远程咨询期间使用类风湿性关节炎疾病影响 (RAID) 评分来监测RA疾病活动的可行性.
- 评估iARPlus基于网络的远程RA管理平台.
主要方法:
- 一项试点研究涉及40名RA患者超过12个月.
- 通过iARPlus平台利用了两次面对面访问和七次远程咨询.
- 使用临床疾病活动指数 (CDAI) 和自我报告的RAID分数测量疾病活动.
主要成果:
- 在基线 (ρ = 0.809) 和随访 (ρ = 0.789) 的CDAI和RAID得分之间观察到强烈的相关性.
- 与Adalimumab相比,接受Janus激酶抑制剂 (JAKis) 治疗的患者在RAID得分中表现出更大的降低和改善的疼痛缓解.
- 接受JAKi治疗的患者表现出更高的疾病缓解率.
结论:
- 在远程咨询设置中,RAID评分有效评估RA疾病活性.
- 在RA中,JAKi治疗在疼痛控制和疾病活性方面似乎比阿达利姆巴更有效.
- 需要进一步的研究来证实RA远程控制的临床和经济优势.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Inflammatory Bowel Disease IV: Pharmacological Management
109
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
109
Autoimmune Disorders
384
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
384
T Cell Types and Functions
945
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
945


